News | April 06, 2022
Revenue growth to moderate, non-Covid-19 revenue to drive profitability
Ind-Ra maintains a neutral outlook for healthcare in FY23
Ind-Ra maintains a neutral outlook for healthcare in FY23
New high-throughput, no-wash assays contribute to the development, manufacture and quality control of safer, more effective biotherapeutics
Under the terms of the agreement, Vipergen will apply its in-living-cell DNA-encoded library (DEL) screening platform to discover novel small-molecule compounds that bind to a selected Theseus kinase target
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
The two-day event will showcase achievements and address issues pertaining to the industry
New simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of innovation, growth and productivity
Highly prestigious award endowed with €500,000 to uphold the United Nations 2030 Agenda
The investment will significantly enhance the development of high-purity lipid systems, essential delivery systems for next generation nucleic acid drugs such as mRNA vaccines
The organization has introduced an advanced FlashMicelle technology which is a combination of ultra-rapid mixing techniques, and a uniquely powerful approach to modify the structure of oil-based formulations to improve their therapeutic efficacy substantially
Company announced that it is accelerating its investment in its Leaps by Bayer impact investment unit with more than 1.3 billion euros funding until end of 2024
Subscribe To Our Newsletter & Stay Updated
